Clinical trials
Withdrawn Phase 2 Leukemia, Myeloid, Acute trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
42 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2007 | 2 |
| 2010 | 1 |
| 2012 | 2 |
| 2013 | 3 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 4 |
| 2019 | 3 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 4 |
| 2025 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Withdrawn | 42 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Masonic Cancer Center, University of Minnesota | 3 |
| Fred Hutchinson Cancer Center | 2 |
| Rush University Medical Center | 2 |
| University of Florida | 2 |
| Wake Forest University Health Sciences | 2 |
| Washington University School of Medicine | 2 |
| Yale University | 2 |
| AVEO Pharmaceuticals, Inc. | 1 |
| Baptist Health South Florida | 1 |
| Columbia University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia, Myeloid, Acute | 42 |
| Myelodysplastic Syndromes | 13 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 9 |
| Congenital Abnormalities | 6 |
| Leukemia | 5 |
| Recurrence | 5 |
| Blast Crisis | 4 |
| Anemia, Refractory, with Excess of Blasts | 3 |
| Burkitt Lymphoma | 3 |
| Leukemia, Erythroblastic, Acute | 3 |
Trials
Showing 1 to 25 of 42. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.